LGVN Q1 2021 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$18M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$376,000-78.0% YoY

Gross Profit

$149,00039.6% margin

Operating Income

-$3M-919.7% margin

Net Income

-$3M-827.4% margin

EPS (Diluted)

$-1.78

QoQ Revenue Growth

-68.1%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$32M

Total Liabilities

$6M

Stockholders' Equity

$26M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$376,000	$2M	-78.0%
Gross Profit	$149,000	$812,000	-81.7%
Operating Income	-$3M	-$213,000	-1523.5%
Net Income	-$3M	-$213,000	-1360.6%

Revenue Segments

AlzheimersAssociationGrantMember

$170,00045%

ClinicalTrialRevenueMember

$165,00044%

MarylandTEDCOGrantMember

$41,00011%